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ABSTRACT 
 
 OBJECTIVE. Islet transplantation is a poorly investigated long-term strategy for 
insulin replacement in patients with diabetes and for complication treatment. We investigated 
if islet transplantation and insulin treatment could relieve diabetic neuropathy and rescue the 
residual endogenous pancreatic β cells. 
 RESEARCH DESIGN AND METHODS. We investigated 5 groups of Sprague 
Dawley rats for 8 months: control rats, diabetic rats, insulin-treated diabetic rats with 
moderate or mild hyperglycaemia and diabetic rats transplanted with microencapsulated 
islets. 
RESULTS. Islet transplantation normalized glycaemia and increased body and 
muscles weight and reduced proteinuria and altered liver function. Transplantation 
significantly improved tail nerve conduction velocity, Na+, K+-ATPase and morphological 
alterations in the sciatic nerve as evidenced by decrease in g-ratio, restored thermal and 
ameliorate mechanical nociceptive thresholds. Morphometrical analysis of pancreas showed a 
significant β cell volume increase in transplanted rats as compared to mild and moderate 
hyperglycaemia rats. 
CONCLUSIONS. Our results show that allogeneic islet transplantation has a positive 
systemic effect in diabetic rats and induces regression of the established neuropathy and 
restitution of the typical characteristics of the islets. These findings strongly indicate the need 
for improving glycaemic control in the attempt not only to reverse established diabetic 
complications but also to improve β cell status in diabetic pancreas.  
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INTRODUCTION 
  
 Type 1 diabetes is characterized by deficiency of insulin secretion due to the loss of β 
cell mass by autoimmunity. Both β cell mass and function decline with increasing diabetes 
duration (1). The consequent chronic hyperglycaemia is believed to be responsible for the 
development of diabetic complications such as neuropathy, retinopathy, nephropathy and 
cardiovascular diseases (2). Forty to 50% of diabetic population develop peripheral and 
autonomic neuropathies (3) and involve a spectrum of functional and structural changes in 
peripheral nerves including sensory loss and pain. The signs of nerve degeneration consist in 
an early decrease of nerve conduction velocity (NCV), of nerve action potential amplitude, 
reduction in Na
+
K
+
ATPase and changes in nociceptive thermal and mechanical thresholds. 
The maintenance of normoglycaemia is the only therapy approved for peripheral neuropathy 
by regulatory bodies in Europe and United States. The DCCT study show that neuropathy 
severity is related to the duration of disease and that improved glucose control reduces 
diabetic complications (2). Currently, the only method of providing physiologically regulated 
control of blood glucose in type 1 diabetic patients is allogeneic islet transplantation. 
 We have previously reported that transplantation of microencapsulated syngeneic 
islets after two month streptozotocin (STZ)-induced diabetes in rats produced 
normoglycaemia, amelioration of impaired nociceptive thresholds, normalization of NCV and 
Na
+
, K
+
-ATPase in the sciatic nerve (4). In kidneys of diabetic rats, we observed mild tubular 
dilatation and tubular cast completely absent in the rats with transplanted islets suggesting 
regression of these early signs of nephropathy (4).  
 There are only few studies on the effect of pancreatic islet transplantation in long lasting 
diabetes and in long-term complications. We then investigated the effect of islet 
transplantation in animals with a long duration of the disease, when, in addition to functional 
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changes, also structural changes are expected to challenge the effectiveness of 
normoglycaemia conditions. 
 We used two strategies to control glycaemia, namely microencapsulated allogeneic islet 
transplantation and daily insulin injections to obtain different levels of glycaemia. To this aim 
we used two groups of diabetic rats: untreated diabetic rats and diabetic rats maintained in 
moderate hyperglycaemia (300-400 mg/dl). After 4 months, diabetic rats with insulin-
regulated glycaemia were divided in 3 groups; the first group was maintained in the same 
conditions, the second underwent transplantation with microencapsulated allogeneic rat islets 
and the last group was treated with insulin to normalize glycaemia. Animals were followed 
for additional 4 months, with overall duration of the study of 8 months from diabetes 
induction.  
 Although it has been reported that normoglycaemia has preventive effects on the 
maintenance of transplanted islets (4; 5), only a few studies addressed the question whether 
islet transplantation may exert such an effect also on endogenous pancreatic islets. Thus, we 
investigated if in STZ-diabetic rats islet transplantation and/or glycaemic control by insulin 
administration could relieve neuropathic complications and neuropathic pain and could rescue 
the residual endogenous pancreatic β cells. 
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RESEARCH DESIGN AND METHODS 
 
Experimental design. Male Lewis and Sprague-Dawley rats (Harlan Laboratories, 
Bresso, Italy) 12 weeks of age were used as donors and recipients, respectively. Animal 
protocol was approved by the Institutional Animal Care and Use Committee of “Mario Negri” 
Institute, Milan, Italy. Animal care
 
and treatment were conducted in conformity with 
institutional
 
guidelines, in compliance with national (DL
 
n. 116/1992, Circ.
 
n. 8/1994) and 
international laws
 
and policies (EEC Council Directive
 
86/609, OJL 358, Dec 1987; NIH 
Guide for the Care and Use of
 
Laboratory Animals, 8
th
 edition, US NRC, 2011). Animals 
were kept on a 12-hour light/dark cycle with free access to water. 
Rats were randomly assigned to three experimental groups: healthy rats (control), 
untreated diabetic rats (hyperglycaemia) and diabetic rats treated subcutaneously with 1 to 15 
IU of human recombinant insulin (Lantus, Sanofi-Aventis SpA, Milano, Italy) to achieve 
glycaemia between 300 and 400 mg/dl (moderate hyperglycaemia). Diabetes was induced by a 
single intraperitoneal injection of STZ (60 mg/kg bw; Sigma, St. Louis, MO). Hyperglycaemia 
was confirmed 48 h after STZ injection by measurements of tail vein blood glucose levels 
using a glucometer tester (Ascensia Elite Bayer, Basel, Switzerland). After 4 months from 
diabetes induction, the moderate hyperglycaemia group was further randomly divided in three 
groups: a group maintained with the same glycaemic control, a group with insulin treatment to 
obtain normoglycaemic conditions (mild hyperglycaemia group) and one group that received 
islet transplantation. The groups of animals were monitored until 8 months from the beginning 
of the study. Body weight and blood glucose concentration, determined by tail bleeding, were 
measured daily.  
Proteinuria was measured in 24-h urine samples collected in metabolic cages at 
baseline and every month by the Coomassie method using a Cobas Mira autoanalyzer (Roche 
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Diagnostic147 Systems, Basel, Switzerland).  
 
Isolation of pancreatic islets. Islets were isolated from the pancreas of Lewis rats (B.W. 
250-300g), using an automatic procedure previously described (4). Briefly, the pancreas of 
anesthetized rats were distended with collagenase P solution (Boehringer-Mannheim, 
Mannheim, Germany), removed and loaded into a digestion chamber at 37°C. When optimum 
digestion time was reached, the chamber was flushed with 4°C Hanks’ balanced salt solution 
(HBSS, Gibson Nitrogen Corporation, Paisley, Scotland) and digested tissue was purified by 
centrifugation on a Histopaque gradient (1.077 g/mL, Sigma, St. Louis, MO). Islets were 
cultured at 37°C in an atmosphere of humidified air + 5% CO2 in RPMI 1640 medium (Life 
Technologies Italia, Monza, Italy), supplemented with 10% foetal bovine serum (EuroClone, 
Pero, Italy). 
 
Encapsulation and transplantation of pancreatic islets. Islet encapsulation was 
performed as previously described (6). Briefly, islets were suspended in 1.7% sodium alginate 
solution (Manugel DMB, Monsanto plc, Surrey, United Kingdom) at a concentration of 1 
islet/µL. The islet-alginate mixture was then extruded through an air jet droplet generator into 
a 100 mmol/L CaCl2 solution. Microcapsules containing 15,000 islets/kg B.W. were implanted 
into the rat peritoneal cavity through a small (1–2 cm) midline incision under isofluorane 
anaesthesia. 
 
 Oral glucose tolerance test. An oral glucose tolerance test (OGTT) was performed 4 
and 8 months from the beginning of the study by oral administration of 1 g/kg B.W. of 
glucose after an overnight fast. Blood samples were taken from the tail vein immediately 
before and 15, 30, 60, 120 and 180 min after glucose administration. Blood glucose 
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concentrations were measured using Ascensia elite strips (Bayer Basel, Switzerland). Total 
area under the curve (AUC) was then calculated. 
 
Behavioural evaluation. Thermal nociceptive threshold to radiant heat was quantified by 
using the paw withdrawal in a hot plate (Ugo Basile, Comerio, Italy) test (7). Withdrawal 
latency was defined as time between placement on the hot plate and time of withdrawal and 
licking of hind paw. The mechanical nociceptive threshold was quantified using the Randal-
Selitto paw withdrawal test (7; 8) with an Analgesy-meter (Ugo Basile, Comerio, Italy), which 
generates a linearly increasing mechanical force. The results represent the maximum pressure 
tolerated by the animals. The hot-plate tests and the Randall-Selitto test were done every four 
weeks. For both determinations animals were tested twice, with a 30-min interval and the 
values were averaged. For mechanical sensitivity the test was done first in the right and then in 
the left leg. 
 
Nerve conduction velocity in the tail nerve. NCV in the tail was measured by using a 
Myto EBNeuro electromiograph (EBNeuro, Firenze, Italy) as previously described (9). 
Briefly, the antidromic NCV in the tail was assessed by placing recording ring electrodes 
distally on the tail while stimulating ring electrodes were placed 5 and 10 cm proximally from 
the recording point. The latencies of the potentials recorded at the two sites after nerve 
stimulation were determined (peak-to-peak stimulus duration 100 ms, filter 1Hz-5MHz) and 
NCV was calculated. Determinations were done under standard conditions in a temperature-
controlled room. Core temperature was maintained at 37°C by using heating pads and lamps. 
 
Plasma and tissue collection. Four and 8 months after the beginning of the study, 
animals were placed under ketamine/xylazine anaesthesia and blood from abdominal aorta 
Page 8 of 32Diabetes
For Peer Review Only
 8
collected. At sacrifice sciatic nerves and pancreas were dissected out. Blood specimens and 
tissues were immediately processed as indicated below. Serum was obtained by centrifugation 
of clotted blood at 2.500 g for 15 minutes at 4° C and used for urea, creatinine, AST and ALT 
determination with an automatic system MIRA PLUS (Horiba ABX Diagnostic Montpellier, 
France) (10). 
 
Plasma Thiobarbituric Acid-Reactive Substances (TBARS). EDTA and glutathione at 
1.34 and 0.65 mmol/L final concentrations, respectively, were immediately added to the 
collected plasma. TBARS levels were determined, as an index of reactive oxygen species 
production, by previously described protocol (11). 
 
Na
+
,K
+
-ATPase activity. These enzymatic activity in the sciatic nerve was assessed by 
spectrophotometric (Ultrospec 2100 pro, Amersham-Biosciences, Cambridge, England) 
method as described (12) by the coupled-enzyme assay (13). Protein content was determined 
with DC Protein Microplate Assay Protocol (Bio RAD Italy, Milan, Italy). 
 
Pathological assessment of sciatic nerve myelinated fibers. The left sciatic nerves were 
removed, fixed by immersion in glutaraldehyde 3% and postfixed in OsO4, epoxy resin 
embedded and used for light microscope observations as previously described (14). Toluidine 
blue stained semithin (1 µ m-thick) sections were prepared from at least two tissue blocks for 
each animal and examined with a Nikon Coolscope light microscope (Nikon Instruments, 
Calenzano, Italy). Counting of myelinated fibers was performed semi-automatically with a 
photomicroscope (Nikon eclipse E200, Leica Microsystem GmbH, Wetzlar, Germany) at a 
magnification of 60X and the morphometric analysis was performed using a QWin automatic 
image analyzer (Leica Microsystems GmbH, Wetzlar, Germany). In randomly selected 
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sections, all myelinated fibers evaluable in the analyzed space were counted according to 
previously reported methods on at least 500 myelinated fibers/nerves (15). At the same time, 
the g-ratio (axonal/myelin diameter) was calculated. Since on the cross sections the shape of 
the axons was not always round, we calculated mean diameter from measured area, assuming 
that ideal shape of the axonwould be a circle.  
 
Pancreas processing. After removal, pancreas was dissected from surrounding tissues 
and fixed by immersion in Bouin’s solution (Diapath, Martinengo, Italy) for 4h at 4°C. 
Samples were dehydrated in ascending concentrations of alcohol and embedded in paraffin. 
For each sample, 3µm sections were obtained and processed for morphometrical analysis by 
immunohistochemical detection of insulin using the alkaline phosphate-Fast red technique. 
Slides were soaked in PBS + 1% BSA for 30 min at room temperature and stained using 
mouse anti-insulin (diluted 1:3000, Sigma, St. Louis, MO) for 2 h at room temperature. Then, 
sections were incubated with horse biotinylated anti mouse antibody (diluted 1:200 Vector, 
Burlingame, CA) for 30 minutes. Slides were then incubated with alkaline phosphatese-
conjugated streptavidin (Boehringer-Mannheim, Mannheim, Germany) and counterstained 
with Harris-type haematoxylin (Bio-Optica, Milano, Italy). 
 
 β cells morphometrical analysis. Tissue sections were examined on an Axiovision 
light microscope (Zeiss, Jena, Germany). For each sampling section, the area was scanned 
with a 20X objective using a MosaiX software. Measurements were performed on digital 
images by an image analysis program (ImageJ , National Institutes of Health, Bethesda, MD). 
The volume density of insulin positive cells was determined by point counting using an 
orthogonal grid with 17x13 lines digitally overlaid on the stained section image. For each 
islet, the number of grid points hitting the positive staining and the negative staining islets 
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were counted. Volume density was calculated as the percent ratio between grid points in the 
positive areas over total points in the pancreatic islet. The mean area of insulin positive cells 
was calculated by multiplying the number of grid points hitting the positive staining by the 
unit area of the grid. Mean volume of islets was calculated using the formula  
     Vi = (K/β) x ( A) 
3/2              
[µm
3
] 
Where A  is the mean area of insulin positive cells, K = 1.1 is a size distribution coefficient 
calculated on the basis of islet size distribution (16) and β = 1.5 is a shape coefficient 
assumed on the basis of minimum and maxim islet axis ratio (17). The density of islets per 
unit volume (NV) was obtained by 
NV = NA/ (D-t)              [µm] 
Where NA is the islet numerical density per unit of pancreatic area  and t the section thickness, 
assumed to be 3µm. The mean islet diameter (D) was obtained from the mean islet volume. 
 
Statistical analysis. Data were analyzed by the analysis of variance (ANOVA) with 
comparisons between groups made by Bonferroni test using the software StatView (SAS 
Institute Inc. Cary, NC). Data are expressed as mean ± standard error of the mean (SEM). 
Statistical significance was assumed for P<0.05. 
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RESULTS 
 
Glycaemia, body weight and urinary excretion of proteins. All animals were carefully 
monitored for the entire 8-month period of the study. Weekly non-fasting blood glucose 
concentration and body weight are reported in Figure 1 A and B. Control rats maintained 
normal values of blood glucose and progressive body weight gain throughout the study. As 
expected, untreated diabetic rats consistently maintained serum glucose levels between 500 
and 600 mg/dl over the 8 months examined and growth was severely impaired during this 
period. Glucose control by insulin injection in order to maintain moderate hyperglycaemia 
was effectively obtained, as shown in Fig. 1A. Improvements in blood glucose control 
overcame the growth impairment observed in diabetic rats throughout the study (Fig. 1B, 
P<0. 01). Normoglycaemia was restored 1 or 2 days after islet transplantation, and was 
maintained for the entire observation period (Fig. 1A). Transplanted rats displayed 
progressive body weight increase reaching values similar to control rats. In rats with intensive 
insulin treatment we did not succeed in complete restoration of normoglycaemia (Fig. 1A). 
Despite mild hyperglycaemia, an improvement in B.W. was recorded also in this group (Fig. 
1B). . The time course of urinary protein excretion is shown in Figure 1C. Diabetic animals 
exhibited significantly higher values of urinary proteins than controls throughout the study. 
Particularly, proteinuria progressively increased in rats with moderate hyperglycaemia, 
averaging 547±161 mg/24h at 8 months. Of interest, in hyperglycaemic animals urinary 
protein excretion did not increase with time and was comparable to that of normal controls at 
study end. Insulin administration was not associated with lowering of proteinuria that was 
significantly higher than in control group during the whole treatment period. Islet 
transplantation exerted an important antiproteinuric effect. Proteinuria in these animals was 
comparable to normal controls (Figure 1C). 
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Blood chemistry. Untreated diabetic rats had a significant increase in BUN, ALT and 
AST values vs. control animals (P < 0.05) at treatment start (data non shown). Insulin 
administration and islets transplantation allowed to achieve normalization of all these kidney 
and liver function parameters  (Table 1). 
 
Plasma TBARS. STZ-induced diabetes significantly triplicates TBARS levels (from 
0.220± 0.022 nmol/mL in controls to 0.731± 0.062 in hyperglycaemic rats; P < 0.01). In 
moderate hyperglycaemia group TBARS levels remained significantly higher as compared to 
control group. Islet transplant and mild hyperglycaemia significantly blunted plasma TBARS 
levels, that averaged 0.401 ± 0.025 and 0.367 ± 0.062 (P< 0.05 and P<0.01, respectively). 
 
OGTT. An OGTT was performed at 4 and 8 months after the STZ injection in all 
groups. Blood glucose concentration and AUC were significantly higher after the glucose 
load in hyperglycaemic rats as compared to control animals at 4 and 8 months (Fig.2 and 
Table 2). Insulin injections to maintain moderate hyperglycaemia lowered the glucose swing 
both at 4 and 8 months (Fig. 2A and B). A more strict glycaemic control in the mild 
hyperglycaemic group did not further improve the OGTT curve (Fig. 2B). Conversely, islet 
transplantation significantly improved both glucose swing and AUC at 8 months 
(P<0.01)(Table 2). 
 
Thermal and mechanical nociceptive thresholds. Figures 3 shows the hind-paw thermal 
and force withdrawal thresholds, measured at baseline and monthly after induction of 
diabetes. Both thermal (hyposensitivity) and mechanical (hypersensitivity) nociceptive 
thresholds were significantly affected by hyperglycaemia starting 2 weeks after STZ injection 
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and persisting for the entire 8 month of testing. It is noteworthy that thermal hypo-algesia was 
highly dependent on glucose level control. In the moderate hyperglycaemia group only a 
long-term treatment triggered a beneficial effect (Fig. 3A), whereas islets transplantation was 
more rapid and effective in restoring thermal sensitivity in about one month. Similar results 
were obtained in mild hyperglycaemia group. Mechanical sensitivity was greatly affected by 
diabetes with a detection threshold decreased by 50-70% after 4 months in all diabetic groups 
(Fig. 3B). Starting from a comparable perception threshold, treatments progressively and 
significantly improved the mechanical perception, islet transplantation being the most 
effective treatment, reaching a 30% reduction from controls at the end of the observation 
period. 
 
NCV. Four months after STZ injection NCV was significantly reduced (P < 0.01) in the 
hyperglycaemic group as compared to controls (data not shown). As expected, in the long-
term study period NCV increased (from 32.7±1.0 to 39.0±1.6 m/sec) in the control group 
whereas it was almost unchanged in diabetic animals (from 24.7±0.8 to 26.9±1.3 m/sec). As 
shown in Figure 3C, at the end of the study islets transplantation triggered a 50% 
improvement in NCV (P<0.01) whereas insulin treatments were less effective with the 
animals still presenting a 25% reduction in NCV. 
 
Na
+
, K
+
-ATPase activity. As shown in Figure 3D, diabetes reduced Na
+
, K
+
-ATPase 
activity in sciatic nerve from 4.81±0.27 in control rats to 2.93±0.10 µmoles/min/mg protein in 
the hyperglycaemic group (P<0.001). It is of interest that islets or insulin treatments in 
diabetic rats induced only a slight reduction in Na
+
, K
+
-ATPase activity (about 10%) that was 
significantly different from hyperglycaemic group (P<0.05). 
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Pathological assessment in sciatic nerve. At light microscopy examination, no evident 
reduction in myelinated fiber density was evident. Very rarely we observed actively 
degenerating fibers in all diabetic animals. Similarly, we observed only rarely mild changes in 
myelin sheath structure in the largest myelinated fibres of diabetic rats, suggesting 
myelinopathy. In view of the overall mild relevance of the pathological changes, the 
differences among the different groups were assessed morphometrically by means of the g-
ratio calculation. Using this quantitative approach, a significant increase in the g-ratio was 
observed in untreated diabetic rats vs. controls (mean 0.686±0.003 vs. 0.647±0.003, P < 
0.01). All treatments significantly reduced g-ratio that averaged 0.629±0.002; 0.655±0.003; 
0.624±0.003 in islet transplantation, mild hyperglycaemia and moderate hyperglycaemia 
respectively  (P < 0.01 for all groups vs. untreated diabetic rats). 
 
 β cells morphometrical analysis. Volume density of β cells in the pancreas of control 
rats averaged 0.83±0.17 and 1.25±0.13% at 4 and 8 months, respectively (Figure 4A). Insulin 
staining in hyperglycaemic rats revealed that β cell volume density was minimal (0.02±0.00 
% positive cells at 4 months and 0.06±0.01% positive cells at 8 months). In contrast, β cells 
volume density in rats with moderate hyperglycaemia averaged 0.11±0.02% and 0.20±0.03% 
at 4 and 8 months, respectively. Comparable β cell volume was estimated in mild 
hyperglycaemic rats as compared to moderate hyperglycaemia. The maximum increase in β 
cell volume occurred in rats with islet transplantation at 8 months with 0.39±0.09% positively 
stained, as compared to rats with moderate hyperglycaemia (P<0.05). 
 Similar results were obtained in the mean area of insulin positive cells indicating that, 
in islet-transplanted group, β cells were organized in clusters resembling islets with almost 
half of the size (Figure 4B). Representative images of insulin stained cells of the groups 
studied at 8 months are shown in Figure 5. Islets from the transplanted group were organized 
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in a structure similar to native islets in pancreas of the control group. 
 Estimation of β cell density showed that there were approximately 17.8±2.2 and 
21.7±1.5 β cells/µm
3
 in islets of control rats at 4 and 8 months, respectively. Hyperglycaemic 
rats showed a substantial reduction in β cell density of almost 83% at 4 months and 87% at 8 
months (Figure 4C). In moderate hyperglycaemic group at 8 months β cell density averaged 
6.1±0.72 β cells/µm
3
. A statistically significant increase in β cell density was observed in islet 
treatment group compared with the moderate hyperglycaemic group (9.2±1.3 vs. 6.1±0.72  β 
cells/µm
3
) (P<0.05). Furthermore, β cell density was slightly lower at 8 months as compared 
to mild hyperglycaemic group.  
 As shown in Figure 6, the volume density of β cells showed a significant linear 
correlation with log values of glycaemia both at 4 (R
2
=0.78) and 8 months (R
2
=0.56) 
indicating that β cell mass was strongly influenced by metabolic conditions. 
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DISCUSSION 
 
In type 1 diabetes immune-mediated reaction induces destruction of pancreatic β cells 
leading to insulin deficiency and hyperglycaemia. Replacement of β cell mass with islet cells 
is considered a viable therapeutic option. Several experimental and clinical studies show that 
pancreatic islet transplantation prevents diabetes complications (18). Peripheral neuropathy is 
one of the most common long-term complication of diabetes causing severe and prolonged 
morbidity (19), characterized by lowering in NCV, axonal degeneration, axoglial disjunction, 
paranodal demyelinization and loss of fiber density (20). In the model of STZ-induced 
diabetic neuropathy the peripheral nervous system damage is represented by evident and 
reproducible functional neurophysiological and biochemical changes (21), paralleled by 
milder pathological changes. We have recently shown that transplantation of syngeneic 
encapsulated islets in diabetic rats induced regression of diabetic complications. Pancreatic 
syngeneic transplantation in the STZ-induced diabetes in the rat ameliorated impaired 
nociceptive thresholds and normalized NCV and Na+, K+-ATPase in the sciatic nerve. In our 
present investigation we have evaluated the effect of the metabolic control in a disease model 
of longer duration, lasting 8 months, on the general conditions of the rats and with a specific 
focus on peripheral nerve damage and islets restoration.  
Our present results show that microencapsulated allogeneic islet transplanted in 
diabetic rats achieved satisfactory glycaemic control, as clearly indicated by a significant 
reduction in glucose excursion after OGTT and a significant increase in animal growth 
suggesting an improvement of the overall diabetic status. We also observed a consistent 
reduction in liver impairment and in proteinuria, as well as a significant antioxidant effects 
both in islet transplanted and mild hyperglycaemic rats. As it might have been expected, 
better metabolic control and improvements in NCV, nociception, and Na
+
, K
+
-ATPase 
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activity, were associated with greater reduction in the biomarker of oxidative stress (plasma 
TBARS levels). In addition, islet transplantation was able to reverse loss of NCV induced by 
diabetes, while insulin treatment only partially prevented NCV reduction. Although other 
studies have reported that islet transplantation was not effective in preventing lesions in 
sciatic nerve of diabetic rats (22), our data are in agreement with those of Sima et al. 
demonstrating that islet transplantation completely prevent the typical slowing of NCV (23). 
We also demonstrated that insulin replacement, by both islet transplantation and intensive 
insulin treatment, counteracts the impairment of Na
+
, K
+
-ATPase activity. This might be a 
mechanism that improves neural function, since both enzymatic activity and NCV are mainly 
related to large myelinated fibers integrity. These results demonstrate that islet transplantation 
effectively reduce peripheral neuropathy in animals with diabetes of long duration. Of note, 
also insulin-treated rats with a better metabolic control had a similar improvement in neural 
function.  
The STZ-induced diabetes model has been extensively used to investigate the function 
of transplanted islets (6;24). These studies were based on the assumption that animals treated 
with STZ, are unable to recover endogenous β cell function. Our data confirmed that 8 
months after diabetes induction by STZ, only residual endogenous β cell mass is present. The 
volume density and the mean area of β cells were significantly reduced in hyperglycaemic 
group as compared with those of control rats (0.056±0.015 and 174±26 vs. 1.249±0.135 and 
938±68, respectively). Histological examination of the pancreas of these rats showed 
scattered insulin positive cells mostly dispersed as single cells or in small clusters in spite of 
well organized and clustered of normal rat pancreas. Also the pancreas of diabetic rats with 
moderate hyperglycaemia, examined before transplantation, contained only a few β cells (in 
average 0.11% insulin positive cells). When the blood glucose concentration was normalized 
by islet transplantation we observed an important increase of insulin positive β cells located 
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inside the pre-existing islets. The mean area of clusters of positive cells was also increased in 
islet-transplanted rats indicating that, in addition to increased number, the regenerated β cells 
were distributed into islet-like structure recreating the typical islet organization. We observed 
a milder increased number of regenerated β cells in rats with mild hyperglycaemia, as 
compared to islet-transplanted group and they had a disorganized distribution. We also 
demonstrated that there is a linear correlation between volume density of β cells and 
glycaemia at single animal level. These results indicate that β cell mass is strongly influenced 
by the metabolic conditions. 
The higher β cells regeneration obtained after islet transplantation compared to 
intensive insulin treatment indicated that re-establishment of normoglycaemia is not the only 
factor involved in islet regeneration and that other factors must be taken into consideration. 
The present investigation was not focussed on the mechanism of islet regeneration in 
transplanted diabetic rats, however we must emphasize that some important issues regarding 
β cell regeneration following islet transplantation need to be addressed and worth to 
investigate, in particular the identification of the source of these new β cells is of milestone 
importance. The question remains as to whether the new β cells originate from 
undifferentiated precursor cells through neogenesis or from mitotic replication of 
differentiated β cells. Understanding how β cell regeneration is regulated could lead to the 
identification of new approaches for enhancing β cell regeneration. 
In conclusion, our present results indicate that normalization of blood glucose by islet 
transplantation improved neural function and induced partial regeneration of β cells with islet-
like organization in the pancreas. These findings strongly indicate the need for improving 
glycaemic control in the attempt not only to reverse established diabetic complications but 
also to improve β cell status in diabetic pancreas.
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FIGURE LEGENDS 
 
Figure 1. (A) Glycaemia and (B) body weight in male SD rats. Values are expressed as mean 
± SE. 
P<0.001 for control vs. all other groups at all time point; 
P<0.001 for hyperglycaemia vs. all other groups at all time point; 
† P<0.05 for control vs. islet transplantation; 
# P<0.05 for hyperglycaemia vs. mild hyperglycaemia; 
••• P<0.001; • p<0.05 for moderate hyperglycaemia vs. islet transplantation; 
 °°° P<0.001; ° p<0.05 for moderate hyperglycaemia vs. mild hyperglycaemia; 
*** P<0.001; * p<0.05 for islet transplantation vs. mild hyperglycaemia. 
(C) Time course of urinary protein excretion. Values are expressed as mean ± SE.  
††† P<0.001 for control vs. all other groups; 
†† P<0.01 for control vs. hyperglycaemia, moderate hyperglycaemia and mild 
hyperglycaemia; 
† P<0.05 for control vs. moderate hyperglycaemia and mild hyperglycaemia; 
### P<0.001 for hyperglycaemia vs. moderate hyperglycaemia and mild hyperglycaemia; 
## P<0.01 for hyperglycaemia vs. islet transplantation; 
# P<0.05 for hyperglycaemia vs. islet transplantation; 
••P<0.01 for moderate hyperglycaemia vs. control; 
• P<0.05 for moderate hyperglycaemia vs. hyperglycaemia; 
§ P<0.05 for mild hyperglycaemia vs. hyperglycaemia; 
** P<0.01 for islet transplantation vs. control; 
 
.
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*P<0.05 for islet transplantation vs. moderate hyperglycaemia. 
 
Figure 2. Oral glucose tolerance test with blood glucose values in male SD rats at 4 (A) and 8 
months (B). Values are expressed as mean ± SE. 
 
Figure 3. (A) Thermal and (B) mechanical nociceptive threshold. (C) Nerve conduction 
velocity in the tail vein at 8 months and (D) Na
+
,K
+
-ATPase activity at 8 months. Values are 
expressed as mean ± SE. 
††† P<0.001 for control vs. hyperglycaemia, moderate hyperglycaemia and mild 
hyperglycaemia; 
†† P<0.01 for control vs. moderate hyperglycaemia and islet transplantation; 
† P<0.05 for control vs. moderate hyperglycaemia, mild hyperglycaemia and islet 
transplantation; 
### P<0.001 for hyperglycaemia vs. mild hyperglycaemia and islet transplantation; 
## P<0.01 for hyperglycaemia vs. mild hyperglycaemia and islet transplantation; 
# P<0.05 for hyperglycaemia vs. moderate hyperglycaemia, mild hyperglycaemia and islet 
transplantation. 
 
Figure 4. ß cell analysis at 4 and 8 months in SD rats. Parameters investigated are volume 
density of ß cells (A), mean area of positive insulin cells (B) and ß cell density per unit of 
volume (C). Results are expressed as mean ±SE. 
††† P<0.001 for control vs. all other groups; 
†† P<0.01 for control vs. hyperglycaemia and islet transplantation; 
### P<0.001 for hyperglycaemia vs. moderate hyperglycaemia and islet transplantation; 
## P<0.01 for hyperglycaemia vs. moderate hyperglycaemia; 
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# P<0.05 for hyperglycaemia vs. moderate hyperglycaemia, mild hyperglycaemia and islet 
transplantation; 
• P<0.05 for moderate hyperglycaemia vs. islet transplantation; 
* P<0.05 for islet transplantation vs. mild hyperglycaemia. 
 
Figure 5. Representative images of stained insulin cells in all the group of rats at the end of 
the study. 
 
Figure 6. Correlation blot between volume density of β cells and log value of glycaemia at 4 
(A) and 8 months (B). Correlation coefficient R
2
=0.78 at 4 months and R
2
=0.56 at 8 months. 
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Table 1. Blood chemistry  at 8 months from diabetes induction.  
† P<0.05 for control vs. hyperglycaemia 
  
BUN 
(mmol/l)   
 
 
ALT 
(IU/l)   
AST 
(IU/l)   
Control 
  
41.1±3.6     0.51±0.04     87.3±12.9     112.8±13.9     
CREATININE 
(mmol/l) 
 
  
  
0.58±0.05   
  
165.9±17.7     75.6±0.
2 
  
  
40.0±4.8    
  
0.55±0.05     
  
62.6±15.8     
  
81.4±20.0     
  
Hyperglycaemia 
51.9±4.5     0.60±0.12     88.1±17.0     90.8±12.3     
47.5±5.0     0.49±0.06      76.0±19.2     
  
80.9±9.4     
† 
Moderate hyperglycaemia 
Mild hyperglycaemia 
Islet transplantation 
137.1±14.3   
† † 
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Table 2. Blood glucose area under the curve at 4 and 8 months from diabetes induction.  
††† P<0.001 vs. hyperglycaemia and vs. moderate hyperglycaemia 
† P<0.05 vs. islet transplantation and mild hyperglycaemia 
*P<0.05 vs. mild hyperglycaemia. 
### P<0.001 vs. all other groups 
••• P<0.001 vs. islet transplantation 
4 months 
AUC (mg/dl/min) 
Control 
Hyperglycaemia 
Moderate hyperglycaemia 
 16142 ± 347    
86735 ± 3379 
46974 ± 4406 
††† 
### 
 15085 ± 268 †††, †  
90746 ± 5609 ### 
36329 ± 2524  
 Mild hyperglycaemia 35851 ± 4692 
Islet transplantation 21944 ± 2180 
• •• 
* 
8 months 
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